BOULDER, Colo .– (AFTERNOON PRAYER) – Edgewise Therapeutics, Inc. announced (NASDAQ: EWTX), a clinical-grade biopharmaceutical company focused on developing oral, small-molecular-weight treatments for rare muscle disorders, today offered an initial public subscription price of 11,000,000 shares of the stock average at a public offer price of $ 16.00 per share. The shares are expected to start trading on Nasdaq World Select Market on March 26, 2021 under the ticker symbol “EWTX. ”The offer is expected to close on March 30, 2021, subject to a normal closing position.
All shares in the offer are offered by Edgewise. The total proceeds to Edgewise from the offer, before discounts and subscription commissions are deducted and costs offered, are expected to be $ 176.0 million. In addition, Edgewise has given subscribers a 30-day option to purchase up to 1,650,000 additional shares of their common stock at the first public offering price, less subscription discounts and commissions.
JP Morgan Securities LLC, Goldman Sachs & Co. LLC and SVB Leerink LLC act as joint book managers for the offer. The Wedbush Securities Inc. acting as co-manager for the offer.
Registration statements related to the offer were submitted by the Securities and Exchange Commission and became effective today. The offer is made directly by guide, and copies are available, when available, from: JP Morgan Securities LLC, c / o Broadridge Financial Solutions, 1115 Long Island Avenue, Edgewood, NY 11717, on phone at (866) 803-9204, or by email at [email protected]; Goldman Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, phone: 1-866-471-2526 or by email [email protected] or from SVB Leerink LLC, Attention: Syndicate Division, One Federal Street, 37th Floor, Boston, MA 02110, by phone at (800) 808-7525, ext. 6105, or by e-mail at [email protected]. Copies of the final preview, when available, associated with the offer are available at www.sec.gov.
This press release does not constitute an offer to sell or bid for offer to purchase these securities, and the sale of such securities would not be in any state or jurisdiction in which the offer, bid or offer would be made. such sale is unlawful prior to your registration or certification under the laws of that state security or jurisdiction.
About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-grade biopharmaceutical company with a focus on the discovery, development and commercialization of innovative treatments for hard, rare muscle disorders for which there is a great unmet medical need. Guided by his holistic drug discovery approach for targeting the muscles as an organ, Edgewise has combined his founding knowledge in muscle biology and small molecular engineering to find the platform possession drugs, build his muscle focus. The Edgewise platform uses purpose-built high-mobility and translational systems that measure unified muscle function in whole organ segments to identify small molecular-weight compounds that regulation of major proteins in skeletal muscle, initially aimed at the treatment of neuromuscular diseases and rare cartilage.